Risk of attention deficit/hyperactivity disorder (ADHD) and other psychiatric disorders in siblings of ADHD probands

Hidalgo-López, Catalina; Gómez-Álzate, Alejandra María; García-Valencia, Jenny; Palacio-Ortíz, Juan David

doi:10.1016/j.rcpeng.2017.06.006

Cited by 4 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, only the MHCRT and MHCRT+Platycladi seed extract treatments succeeded to significantly increase the expression of β-EP proteins and significantly decreased the expression of PG proteins (p < 0.05) (Figure 2). Methylphenidate hydrochloride is a central stimulant, that is recommended by the United States Food and Drug Administration (FDA) for the treatment of ADHD [9]. It has a history of more than 50 years and is still the first option for the clinical treatment of ADHD.…”

Section: Expression Of β-Ep Pg Ip3 and Glu In Rat Serummentioning

confidence: 99%

“…Its main mechanism is to block the reuptake of mono-amine neurotransmitters, such as noradrenaline and dopamine, into presynaptic neurons, promotes the release of monoamine neurotransmitters and increases the concentration of dopamine and noradrenaline in the synaptic space. Methylphenidate has been shown to improve the excitability of the awakening centre of children, and improve the attention and self-control ability, having an important role in improving the corresponding symptoms associated with ADHD [9]. Cypress is the dry seed of Platycladus orientalis (L.) Franco, which is mainly produced in Shandong, Henan and other places in Asia.…”

Section: Expression Of β-Ep Pg Ip3 and Glu In Rat Serummentioning

confidence: 99%

See 1 more Smart Citation

The Effect of Methylphenidate Hydrochloride Combined With Platycladi Seed Extract on Attention Deficit Hyperactivity Disorder in a Murine Model

Zhao¹

2021

FARMACIA

View full text Add to dashboard Cite

The study aimed to evaluate the therapeutic effect and the underlying mechanism of methylphenidate hydrochloride combined with Platycladi seed extract on attention deficit hyperactivity disorder (ADHD) in a murine model. Forty-eight SPF male SHR rats were divided into 4 groups as follows: a rat model of attention deficit hyperactivity disorder that received 10 mL/kg bw/day saline solution, a methylphenidate hydrochloride group treated with 3.75 mg/kg bw/day methylphenidate hydrochloride, a Platycladi seed extract group treated with 9 mg/kg bw/day Platycladi seed extract, a methylphenidate hydrochloride (MHCRT) combined with Platycladi seed extract group treated with 3.75 mg/kg bw MHCRT plus 9 mg/kg bw/day Platycladi seed extract. Twelve Wistar Kyoto rats were used as a normal group that received 10 mL/kg bw/day saline solution. After 14 days of treatment the combination of MHCRT and Platycladi seed extract significantly reduced the serum NE (norepinephrine) level in rats and significantly increased the DA (dopamine) and 5-HT (serotonin) levels along with improving neurobehavioral changes related with ADHD with a superior effect compared with the use of Platycladi seed extract or MHCRT alone.Regarding the protein expression level in brain tissue when associated to the standard treatment with MHCRT, Platycladi seed extract additively increased the effect of MHCRT and succeeded to significantly increase the expression of GIT1 (ARF GTPaseactivating protein), CDH13 (cadherin 13), BDNF (brain-derived neurotrophic factor), CaM (calmodulin) and NET (adrenergic transporters) and significantly decreased the expression of LPHN3 (latrophilin 3) compared with the model group. In serum, the association of Platycladi seed extract with MHCRT additively increased the effect of MHCRT alone on increasing the protein level of β-EP (betaendorphin), IP3 (inositol triphosphate) and Glu (Glutamine synthetase) and decreased PG (plakoglobin) level compared with the model group. In conclusion, Platycladi seed extract can potentiate the effect of standard MHCRT treatment by regulating the expression of neurotransmitters in an ADHD murine model. RezumatStudiul a urmărit evaluarea efectului terapeutic și mecanismul ce stă la baza acțiunii clorhidratului de metilfenidat, combinat cu extractul din semințe de Platycladi, asupra unui model murin de hiperactivitate cu deficit de atenție (ADHD). Patruzeci și opt de șobolani masculi SPF spontan hipertensivi (SHR) au fost împărțiți în 4 grupuri după cum urmează: un grup de șobolani cu ADHD care a primit 10 mL/kgc/zi ser fiziologic, un grup de șobolani care a primit 3,75 mg/kgc/zi metilfenidat, un grup de șobolani care a primit 9 mg/kgc/zi extract de semințe de Platycladi, un grup tratat cu 9 mg/kg corp/extract de semințe de Platycladi și 3,75 mg/kgc metilfenidat (MHCRT). Doisprezece șobolani Wistar Kyoto au fost folosiți ca și grup normal care a primit 10 mL/kgc/zi ser fiziologic. După 14 zile de tratament, combinația utilizată a redus semnificativ nivelul seric de NE (norepinefrină) la șobolani și a...

show abstract

Section: Expression Of β-Ep Pg Ip3 and Glu In Rat Serummentioning

confidence: 99%

Section: Expression Of β-Ep Pg Ip3 and Glu In Rat Serummentioning

confidence: 99%

The Effect of Methylphenidate Hydrochloride Combined With Platycladi Seed Extract on Attention Deficit Hyperactivity Disorder in a Murine Model

Zhao¹

2021

FARMACIA

View full text Add to dashboard Cite

show abstract

“…ADHD is defined through clinical observation of the emergence, typically after 6 years of age (Halperin & Marks, 2019), of two types of behavioral manifestations: inattentiveness and/or hyperactivity and impulsiveness (American Psychiatric Association, 2013). Twin, family, and DNA-based studies showed that both ASD and ADHD are highly heritable, indicating that genetic factors explain most of the liability of these conditions (Hidalgo-Lopez, Gomez-Alzate, Garcia-Valencia, & Palacio-Ortiz, 2019; Larsson, Chang, D-Onofrio, & Lichtenstein, 2014; Miller et al, 2019; Tick, Bolton, Happé, Rutter, & Rijsdijk, 2016). Substantial clinical overlap has been found between ADHD and other neurodevelopmental conditions, in particular ASD (Hollingdale, Woodhouse, Young, Fridman, & Mandy, 2019; Lai et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

Look duration at the face as a developmental endophenotype: elucidating pathways to autism and ADHD

Gui

Mason

Gliga³

et al. 2020

Dev Psychopathol

View full text Add to dashboard Cite

Identifying developmental endophenotypes on the pathway between genetics and behavior is critical to uncovering the mechanisms underlying neurodevelopmental conditions. In this proof-of-principle study, we explored whether early disruptions in visual attention are a unique or shared candidate endophenotype of autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD). We calculated the duration of the longest look (i.e., peak look) to faces in an array-based eye-tracking task for 335 14-month-old infants with and without first-degree relatives with ASD and/or ADHD. We leveraged parent-report and genotype data available for a proportion of these infants to evaluate the relation of looking behavior to familial (n = 285) and genetic liability (using polygenic scores, n = 185) as well as ASD and ADHD-relevant temperament traits at 2 years of age (shyness and inhibitory control, respectively, n = 272) and ASD and ADHD clinical traits at 6 years of age (n = 94). Results showed that longer peak looks at the face were associated with elevated polygenic scores for ADHD (β = 0.078, p = .023), but not ASD (β = 0.002, p = .944), and with elevated ADHD traits in mid-childhood (F(1,88) = 6.401, p = .013, $\eta _p^2$ =0.068; ASD: F (1,88) = 3.218, p = .076), but not in toddlerhood (ps > 0.2). This pattern of results did not emerge when considering mean peak look duration across face and nonface stimuli. Thus, alterations in attention to faces during spontaneous visual exploration may be more consistent with a developmental endophenotype of ADHD than ASD. Our work shows that dissecting paths to neurodevelopmental conditions requires longitudinal data incorporating polygenic contribution, early neurocognitive function, and clinical phenotypic variation.

show abstract

“…This finding was similar to Mclntyre et al (2013), Nierenberg et al (2005), Taman et al (2008), and karaahmet et al (2013) studies where the age-onset was about 5 years earlier compared to non-AADHD[ 7 , 29 , 32 ]. It has been suggested that ADHD makes people more vulnerable to other major psychiatric disorders, as secondary disorder or disorders with common inherited vulnerability [ 39 , 40 ]. This important finding should be considered by mental health workers to screen for children and adolescents with attention-deficit and hyperactivity-impulsivity problems among their referrals.…”

Section: Discussionmentioning

confidence: 99%

ADHD in adults with major depressive or bipolar disorder: does it affect clinical features, comorbidity, quality of life, and global functioning?

et al. 2022

View full text Add to dashboard Cite

Background This study compared clinical characteristics, concurrent disorders, level of function, and quality of life in adults with bipolar (BD) or major depressive disorder (MDD) in those with/without adult attention defici1t hyperactivity disorder (AADHD). Methods The participants were recruited among adult inpatients and outpatients with MDD or BD in their current partial remission in a psychiatric hospital. They were evaluated using the interview for adults with ADHD (DIVA-5), Conners’ Adult ADHD Rating Scales–Self-Report-Screening Version (CAARS-SR-SV), Structured Clinical Interview for DSM-V (SCID-5), Beck Depression Inventory-II and Young Mania Rating Scale, Global Assessment of Functioning (GAF) and World Health Organization Quality of Life Scale-Brief (WHOQoL-BREF). Results In those with MDD (n = 105) and BD (n = 103), AADHD was detected as 13.3% and 16.5%, respectively. The inattentive presentation was the most prevalent type among patients with AADHD. Compared to the patients without AADHD, the results regarding the prevalence of comorbidities, suicidal attempts, severity of affective episodes, the early emergence of the affective disorders, and level of quality of life and global functioning were poorer in the group with AADHD (p < 0.05). Limitations The participants were individuals with major depressive or bipolar type I disorder with a mostly manic episode, chosen among the referrals to a tertiary psychiatric hospital with high comorbidity and more severe psychopathology. This may limit the generalizability of the findings. Conclusion ADHD was common in adults with MDD and BD, along with high psychiatric comorbidity and negative consequences. Clinicians are suggested to screen adults with mood disorders for the symptoms of ADHD for a more precise and comprehensive diagnosis and to provide a more appropriate therapeutic intervention.

show abstract

Risk of attention deficit/hyperactivity disorder (ADHD) and other psychiatric disorders in siblings of ADHD probands

Cited by 4 publications

References 15 publications

The Effect of Methylphenidate Hydrochloride Combined With Platycladi Seed Extract on Attention Deficit Hyperactivity Disorder in a Murine Model

The Effect of Methylphenidate Hydrochloride Combined With Platycladi Seed Extract on Attention Deficit Hyperactivity Disorder in a Murine Model

Look duration at the face as a developmental endophenotype: elucidating pathways to autism and ADHD

ADHD in adults with major depressive or bipolar disorder: does it affect clinical features, comorbidity, quality of life, and global functioning?

Contact Info

Product

Resources

About